Genetic Technologies Limited (GENE)

$0.9275

+0.03 (+3.06%)
Rating:
Recommendation:
Neutral
Symbol GENE
Price $0.9275
Beta 0.877
Volume Avg. 0.03M
Market Cap 20.291M
Shares () -
52 Week Range 0.9-2.12
1y Target Est -
DCF Unlevered GENE DCF ->
DCF Levered GENE LDCF ->
ROE -18.50% Sell
ROA -16.65% Sell
Operating Margin -
Debt / Equity 26.60% Neutral
P/E -
P/B 1.20 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GENE news


Dr. Jerzy Muchnicki
Healthcare
Diagnostics & Research
NASDAQ Capital Market

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.